In some cases of myeloma, excess protein in the blood can cause a condition called hyperviscosity syndrome. The type and amount of immunoglobulin protein can result in thickening the blood beyond normal blood viscosity, which may result in alteration in a variety of bodily, including mental, proc...
Multiple myeloma (MM) is a biologically and clinically heterogeneous malignancy of terminally differentiated plasma cells (PCs), which abnormally proliferate in the bone marrow (BM), and typically secrete non-functional monoclonal immunoglobulin (Ig) in serum and urine. The stages of MM development us...
Multiple Myeloma. Multiple myeloma(MM) is a rare, malignant tumor of plasma cells that arises in the bone marrow and usually secretes large amounts ofimmunoglobulin. The finding of neoplastic plasma cells in blood samples or smears is rare.Dogsare affected more frequently than other species, but...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Regulatory T cells have been shown to have massive infiltration of a variety of solid tumors in humans and mice as well as increased cellular levels in the peripheral blood. Questions 1. What changes occur in the number and function of Treg cells in patients with multiple myeloma?
Presenting signs and symptoms of multiple myeloma (MM) include bone pain, pathologic fractures, weakness, anemia, infection (often pneumococcal), hypercalcemia, spinal cord compression, and renal failure. In approximately 30% of cases, MM is discovered through routine blood screening when patients are...
Extramedullary multiple myeloma (EMM) is an aggressive subentity of multiple myeloma, characterized by the ability of a subclone to thrive and grow independent of the bone marrow microenvironment, resulting in a high-risk state associated with increased
Some medicines help chemotherapy drugs work better. That’s also true if your cancer comes back (called a relapse), or if your current treatment doesn’t help you enough or stops working (called “refractory” multiple myeloma). Your doctor may combine chemo with drugs: ...
At present, the characteristics of double-hit multiple myeloma (DHMM) are unknown. We retrospectively analyzed the clinical data from 433 new diagnosed MM patients and found that DHMM have a higher β2-MG level and percentage of bone marrow plasma cell.
blood cancer worldwide and remains an incurable disease.7In 2024, it was estimated that more than 35,000 people will be diagnosed with multiple myeloma in the U.S. and more than 12,000 people would die fr...